Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma
Furqan M. et al, (2025), Pharmaceutics, 17, 549 - 549
A High-Throughput Drug Repurposing Strategy to Treat TBX2 and/or TBX3 Dependent Cancers.
Bleloch JS. et al, (2024), Cancer medicine, 13
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
Kent D. et al, (2024), Hepatology (Baltimore, Md.)
Improving the representativeness of UK's national COVID-19 Infection Survey through spatio-temporal regression and post-stratification.
Pouwels KB. et al, (2024), Nature communications, 15
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells
Baugh R. et al, (2024), Journal for ImmunoTherapy of Cancer, 12, e008460 - e008460
Optimized protocol for CRISPR knockout of human iPSC-derived macrophages
Navarro-Guerrero E. et al, (2024), STAR Protocols, 5, 102903 - 102903
Author Correction: C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption.
Sharma AB. et al, (2023), Nature communications, 14
Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.
Bešević J. et al, (2023), Journal of epidemiology and community health
Selective ROCK Inhibitor Enhances Blood Flow Recovery after Hindlimb Ischemia
Fayed HS. et al, (2023), International Journal of Molecular Sciences, 24, 14410 - 14410
Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells
Athanasiadis P. et al, (2023), iScience, 26
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK
Buckell J. et al, (2023), Scientific Reports, 13
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
Wei J. et al, (2023), Nature Communications, 14
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023), Clinical Cancer Research, 29, 1631 - 1642
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)